Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 73,737 | 264,033 | 256,472 | 27,767 | 542,709 |
| Gross Profit | 73,737 | 264,033 | 256,472 | 27,767 | 542,709 |
| Operating Expenses | 214,997 | 223,224 | 212,366 | 193,317 | 161,507 |
| Operating Income | -141,260 | 40,809 | 44,106 | -165,550 | 381,202 |
| Interest Expense | 23,846 | 22,505 | 21,694 | 24,382 | 21,639 |
| Other Income | 27,541 | 9,967 | 13,709 | 10,843 | 10,053 |
| Pre-tax Income | -137,565 | 28,271 | 36,121 | -179,089 | 369,616 |
| Income Tax | 7 | 29 | 20,000 | -437 | 1,753 |
| Net Income Continuous | -137,572 | 28,242 | 16,121 | -178,652 | 367,863 |
| Minority Interests | -4,840 | -2,569 | 39,871 | -3,411 | -2,582 |
| Net Income | $-132,732 | $30,811 | $-23,750 | $-175,241 | $370,445 |
| EPS Basic Total Ops | -0.93 | 0.22 | -0.14 | -1.26 | 2.78 |
| EPS Basic Continuous Ops | -0.97 | 0.21 | 0.16 | -1.28 | 2.76 |
| EPS Diluted Total Ops | -0.93 | 0.22 | -0.11 | -1.26 | 2.75 |
| EPS Diluted Continuous Ops | -0.97 | 0.20 | 0.18 | -1.28 | 2.74 |
| EPS Diluted Before Non-Recurring Items | -0.93 | 0.22 | -0.18 | -1.26 | 2.75 |
| EBITDA(a) | $-136,750 | $47,199 | $49,248 | $-161,084 | $384,498 |